|Systematic (IUPAC) name|
|(what is this?)|
JNJ-7777120 is a drug being developed by Johnson & Johnson Pharmaceutical Research & Development which acts as a potent and selective antagonist at the histamine H4 receptor. It has antiinflammatory effects, and has been demonstrated to be superior to traditional antihistamines in the treatment of pruritus (itching).
- Jiang W, Lim HD, Zhang M et al. (July 2008). "Cloning and pharmacological characterization of the dog histamine H(4) receptor". Eur. J. Pharmacol. 592 (1–3): 26–32. doi:10.1016/j.ejphar.2008.06.095. PMID 18639542.
- Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, Nguyen S, Riley JP, Sun S, Williams KN, Edwards JP, Karlsson L. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. Journal of Pharmacology and Experimental Therapeutics. 2004 Apr;309(1):404-13. PMID 14722321
- Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. Journal of Allergy and Clinical Immunology. 2007 Jan;119(1):176-83. PMID 17208599
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|